After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Recently, Yahoo Finance discussed the stock, revealing that Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
GILD belongs to the Healthcare sector of the NASDAQ while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $75.12 and fluctuated between $75.43 as its day high and $73.67 as its day low. The current market capitalization of Gilead Sciences, Inc. is $93.58B. A total of 8.91 million shares were traded on the day, compared to an average of 7.34M shares.
In the most recent transaction, Parsey Merdad sold 8,230 shares of GILD for 72.74 per share on Feb 29 ’24. After the transaction, the Chief Medical Officer now owns 92,706 company shares. In a previous transaction on Feb 28 ’24, Parsey Merdad sold 2,000 shares at 73.18 per share. GILD shares that Chief Medical Officer owns now total 100,936.
Among the insiders who bought shares, GILEAD SCIENCES, INC. acquired of 910,000 shares on Feb 12 ’24 at a per-share price of $22.00. This resulted in the 10% Owner holding 4,126,119 shares of GILD after the transaction. In another insider transaction, GILEAD SCIENCES, INC. bought 15,238,095 shares at $21.00 per share on Jan 29 ’24. Company shares held by the 10% Owner now total 30,061,124.
Dividend
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Gilead Sciences, Inc. pays an annual dividend of $3.00, resulting in a dividend yield of 3.99%, and it has a price to earnings (P/E) ratio of 16.68. GILD’s most recent ex-dividend date was 3/14/2024 when it declared a $0.77 quarterly dividend that was paid in cash on 3/28/2024. Previously, the company paid the dividend on 12/28/2023 with an ex-dividend date of 12/14/2023. The GILD stock dividend was $0.75 per share in cash.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, GILD has a high of $87.86 and a low of $71.37.
As of this writing, GILD has an earnings estimate of $1.58 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $1.97 per share and a lower estimate of $1.21. The company reported an EPS of $2.29 in the last quarter, which was 19.30% higher than expectations of $1.92.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $18.33, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.95.
